nci logo
NIH
U.S. National Institutes of Health National Cancer Institute

Previous Version: SEER Cancer Statistics Review, 1975-2003

On this page:

Contents of the CSR

Note: A site variable with groupings for Kaposi Sarcoma and Mesothelioma was used in the calculation of statistics.

The files on this page are provided in Portable Document Format (PDF).

Summary Figures and Tables
(Excerpts from Overview)
CSR Sections Pages Grouped By Topic
  1. Overview in a Single PDF
  2. All Sites
  3. Brain and Other Nervous
  4. Breast
  5. Cervix Uteri
  6. Colon and Rectum
  7. Corpus Uteri
  8. Esophagus
  9. Hodgkin Lymphoma
  10. Kaposi Sarcoma
  11. Kidney and Renal Pelvis
  12. Larynx
  13. Leukemia
  14. Liver and Bile Duct
  15. Lung and Bronchus
  16. Melanoma of the Skin
  17. Mesothelioma
  18. Myeloma
  19. Non-Hodgkin Lymphoma
  20. Oral Cavity and Pharynx
  21. Ovary
  22. Pancreas
  23. Prostate
  24. Stomach
  25. Testis
  26. Thyroid
  27. Urinary Bladder
  28. Childhood Cancer
  29. Childhood Cancer by the ICCC    

Return to top

Revision History

Date Revision Affected Pages
06/14/2006 The prevalence counts were updated to include a change in race recode. Prior to the CSR's release, the Indian Health Service Link was used to code a small portion of the white population as American Indian/Alaska Native. The prevalence counts were generated before this coding change and have been updated to reflect the coding change. The update only changed a small number of prevalence counts, and only the pages with updated counts are listed as affected pages. Tables changed:
I-17, I-18, II-16, VI-23, XXIII-12

Tables appear in the following topics:

06/06/2006 The data series on the graph were mislabeled for all of the series. The series are now correctly labeled. Figure XVI-3

Figure appears in the following section:
Section 16: Melanoma of the Skin

05/15/2006 The incidence and mortality rates for white and black males were mislabeled. The delay-adjusted incidence rates for white males were labeled as black males, and vice-versa. The same type of mislabeling occurred for the mortality rates as well. Figure XXIII-4

Figure appears in the following section:
Section 23: Prostate

05/4/2006 The survival rates in Table I-6 were originally suppressed if there were fewer than 25 cases alive at the end of the interval. The survival rates are now suppressed if there are fewer than 16 cases alive at the end of the interval. Table I-6

Table appears in the following topics:

05/4/2006 In Table IV-10, relative survival rates for in situ breast cancer were improperly suppressed. The rates are now shown where there are 16 or more cases alive at the end of the interval. Table IV-10

Table appears in the following topics:

05/4/2006 The period survival rates in Table XVII-4 were originally suppressed if there were fewer than 25 cases alive at the end of the interval. The period survival rates are now suppressed if there are fewer than 16 cases alive at the end of the interval. Consequently, the period rate for black females is no longer suppressed.
Table XVII-4

Table appears in the following topics:

05/3/2006 The year labels for American Indian/Alaska Native rates and trends were changed -- from 1999-2002 to 2000-2003 for rates, and from 1994-2002 to 1994-2003 for trends. Tables changed:
I-19, I-22, I-23, I-24

Tables appear in the following topics:

Return to top

Suggested Citation

All material in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.

Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ,  Clegg L, Eisner MP, Horner MJ, Howlader N, Hayat M,  Hankey BF,  Edwards BK (eds). SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2003/, based on November 2005 SEER data submission, posted to the SEER web site, 2006.

Return to top